Artificial insemination represents one of the foundational breakthroughs in modern reproductive medicine, providing individuals and couples facing diverse forms of infertility with a scientifically validated pathway toward conception. By directly bypassing anatomical and physiological barriers through the deliberate mechanical placement of prepared spermatozoa into the female reproductive tract, this medical intervention has redefined biological family-building across the globe.
Artificial Insemination
1. Concise Definition
Artificial insemination (AI) refers to the medical or biological procedure in which prepared spermatozoa are manually introduced into the female reproductive tract—most commonly within the uterine cavity, cervix, or fallopian tubes—by instrumental means rather than through sexual intercourse, with the explicit intention of achieving fertilization and clinical pregnancy. In contemporary reproductive medicine, it encompasses procedures such as intrauterine insemination (IUI), intracervical insemination (ICI), and intratubal insemination (ITI), utilizing either partner sperm or donor specimens.
Beyond its fundamental clinical definition, artificial insemination serves as a core therapeutic intervention within assisted reproductive technology (ART). It represents a minimally invasive, cost-effective first-line strategy designed to overcome diverse physiological, immunological, and anatomical impediments to natural reproduction, while simultaneously playing a pivotal role in veterinary theriogenology and species conservation programs worldwide.
2. Etymology & Linguistic Origin
The term artificial insemination is an analytical compound derived from Classical Latin roots. The modifier artificial stems from the Latin adjective artificialis, which originates from the compound noun artificium, formed by joining ars (meaning “art,” “craft,” “skill,” or “method”) and the verb facere (meaning “to make” or “to do”). Historically, artificial conveyed that an event or object was brought about by deliberate human craft, technique, and intervention rather than occurring spontaneously through unassisted natural processes.
The noun insemination traces directly to the Latin verb inseminare, a compound formed from the prefix in- (“into” or “within”) and seminare (“to sow” or “to plant”), which itself derives from the noun semen (genitive seminis, meaning “seed”). In classical agricultural usage, the root referred to the deliberate sowing of seed into tilled soil. By the late eighteenth and early nineteenth centuries, European naturalists and physicians adopted the composite phrase to denote the scientific deposition of seminal fluid into the female genital system, formalizing a medical nomenclature that distinguished technological conception from traditional coitus.
3. Pronunciation & Grammatical Form
In standard English phonetics, the term is pronounced using the International Phonetic Alphabet (IPA) as follows: British English /ˌɑː.tɪˈfɪʃ.əl ɪnˌsɛm.ɪˈneɪ.ʃən/ and American English /ˌɑːr.t̬əˈfɪʃ.əl ɪnˌsɛm.əˈneɪ.ʃən/. The initial word carries primary stress on the third syllable (-fish-), while the primary stress in insemination falls upon the fourth syllable (-nay-).
Grammatically, artificial insemination functions as an open compound noun that is generally non-countable when denoting the overarching medical practice or biological concept (e.g., “advances in artificial insemination”). It can, however, function as a countable noun when referring to discrete clinical encounters, procedures, or treatment cycles (e.g., “she underwent three consecutive artificial inseminations”). The verbal form is expressed as “to artificially inseminate” (transitive verb), and the practitioner is periodically referred to as an “inseminator,” predominantly within veterinary and theriogenological literature.
4. Detailed Conceptual Explanation
The operational framework of artificial insemination is grounded in overcoming biological friction within the female reproductive tract. In unassisted human reproduction, hundreds of millions of spermatozoa are deposited in the acidic environment of the vagina during coitus. A minuscule fraction navigates the protective barrier of cervical mucus, passes through the endometrial cavity, traverses the uterotubal junction, and ascends into the ampulla of the fallopian tube, where fertilization typically occurs. Pathological states such as severe cervical stenosis, antisperm antibodies, hostile cervical mucus, oligospermia, asthenozoospermia, or anatomical abnormalities can prevent viable spermatozoa from reaching the ovum. Artificial insemination remedies these deficits by delivering a concentrated volume of motile, washed spermatozoa directly into an optimal anatomical location, thereby dramatically shortening the transit distance and bypassing major physical and biochemical obstacles.
In human clinical practice, modern artificial insemination is almost universally carried out as intrauterine insemination (IUI). The procedure necessitates laboratory processing of raw ejaculate, known as sperm washing. Raw seminal plasma contains significant concentrations of prostaglandins, bacteria, cellular debris, and inflammatory proteins. If injected directly into the non-sterile uterine cavity, unwashed semen can induce severe uterine cramping, anaphylactic reactions, and pelvic inflammatory disease. Consequently, clinical laboratories deploy density gradient centrifugation or swim-up separation techniques to isolate highly motile, morphologically normal spermatozoa suspended in physiological culture media, removing the liquid seminal plasma entirely.
The timing of artificial insemination must be synchronized precisely with ovulation. Because the human oocyte remains viable for fertilization for roughly twelve to twenty-four hours after release from the ovarian follicle, and capacitated spermatozoa maintain peak fertilizing capability for approximately twenty-four to forty-eight hours within the upper genital tract, timing errors represent the most common cause of treatment failure. Clinicians monitor foliculogenesis via transvaginal ultrasonography and track surges of luteinizing hormone (LH) in serum or urine. Frequently, an injection of human chorionic gonadotropin (hCG) is administered to act as a surrogate LH surge, inducing ovulation approximately thirty-six hours later, at which point the insemination procedure is executed via a sterile, flexible polyethylene catheter passed atraumatically through the cervical os.
The scope of artificial insemination extends across two broad modalities based on the genetic origin of the semen: homologous insemination, historically termed Artificial Insemination with Husband’s or Partner’s sperm (AIH), and heterologous insemination, known as Artificial Insemination with Donor sperm (AID) or therapeutic donor insemination (TDI). Homologous insemination addresses mild-to-moderate male subfertility, psychogenic or neurological ejaculatory dysfunction (such as anejaculation secondary to spinal cord injury), and unexplained female infertility. Donor insemination, by contrast, is deployed in cases of severe non-obstructive azoospermia, high risk of transmission of severe hereditary genetic disorders from the male partner, and as an essential family-building pathway for single women and same-sex female couples.
5. Historical Development
The historical trajectory of artificial insemination traces back through centuries of documented scientific experimentation. While fourteenth-century Arabian historical lore mentions rival tribes surreptitiously inseminating enemy mares with semen gathered from inferior stallions to degrade bloodlines, the earliest authenticated, documented scientific achievement belongs to the Italian Catholic priest, biologist, and physiologist Lazzaro Spallanzani in 1780. Spallanzani successfully carried out artificial insemination in a canine bitch, which culminated sixty-two days later in the delivery of three healthy puppies, proving definitively that mechanical introduction of semen was sufficient to trigger embryonic development without copulation.
The clinical translation of this veterinary success to human medicine occurred shortly thereafter in London. In the late 1770s or early 1780s, the eminent Scottish surgeon and anatomist John Hunter successfully advised a patient suffering from severe hypospadias to collect his split ejaculate using a warm syringe and introduce it into his wife’s vaginal vault, resulting in a successful pregnancy and birth. Hunter’s pioneering work remained largely unpublished during his lifetime but was formally documented in 1799 by his brother-in-law, Sir Everard Home. Decades later, in 1866, the American gynecologist J. Marion Sims performed fifty-five documented uterine inseminations on six women, yielding one successful pregnancy, though he subsequently disavowed the procedure due to high failure rates and infectious complications stemming from the lack of germ theory and sperm processing protocols at the time.
At the turn of the twentieth century, Russian scientist Ilya Ivanovich Ivanov emerged as the foundational architect of large-scale animal artificial insemination, refining techniques in horses, cattle, and sheep, which revolutionized global agriculture and livestock breeding. In human medicine, the mid-twentieth century brought critical technological breakthroughs, most notably the discovery of the cryoprotective properties of glycerol by Christopher Polge, Audrey Smith, and Alan Parkes in 1949. This discovery enabled the long-term cryopreservation of human semen in liquid nitrogen, leading directly to the establishment of the first human sperm banks in the 1950s and 1970s. The latter half of the twentieth century saw the rapid evolution of density-gradient centrifugation techniques, sterile plastic catheter design, and precise endocrine monitoring, transforming artificial insemination from a rudimentary, variable intervention into a highly standardized, predictable subfield of reproductive medicine.
6. Theoretical Foundations
Artificial insemination is grounded within the intersection of reproductive endocrinology, cellular gamete physiology, and transport biomechanics. At its biological core lies the theory of gamete transport and capacitation. In mammalian physiology, freshly ejaculated spermatozoa lack the immediate competence to fertilize an egg; they must undergo capacitation, a cascade of biochemical changes involving cholesterol efflux from the sperm plasma membrane, an influx of calcium and bicarbonate ions, and the hyperactivation of motility. Under natural conditions, these alterations are stimulated by interactions with the female reproductive tract lining and cervical mucus. In modern clinical IUI, laboratory processing protocols mimic these physiological triggers, initiating in vitro capacitation so that spermatozoa are biochemically primed upon uterine deposition.
A second foundational pillar is the threshold hypothesis of male fecundity. Clinical research in theriogenology and human andrology demonstrates that the probability of conception per ovulatory cycle correlates positively with the total motile sperm count (TMSC) delivered to the site of fertilization, up to a biological plateau. Natural intercourse deposits millions of cells, but only a fraction survives the acidic vaginal environment. By directly injecting an enriched cohort of motile gametes past the cervix, artificial insemination shifts the dose-response curve, allowing individuals with reduced baseline semen parameters to surpass the minimum threshold required for successful fertilization.
Furthermore, artificial insemination interfaces with the mathematical models of cumulative pregnancy rates and the law of proportional hazards in reproductive epidemiology. Infertility medicine recognizes that fecundability (the probability of achieving a pregnancy within a single menstrual cycle) follows a predictable non-linear distribution. When artificial insemination is paired with mild ovarian stimulation, the recruitment of multiple follicles combined with optimized gamete timing elevates cycle-specific fecundability, demonstrating the additive theoretical benefit of synchronizing controlled endocrine stimulation with targeted mechanical gamete delivery.
7. Key Components, Types & Dimensions
Artificial insemination encompasses multiple variations defined by the anatomical site of deposition, the source of the gametes, and the accompanying endocrine protocols. These dimensions can be categorized as follows:
- Intrauterine Insemination (IUI): The clinical gold standard in human assisted reproduction. A washed, concentrated sample of motile spermatozoa (typically 0.2 to 0.5 mL) is deposited directly into the endometrial cavity using an ultra-fine, flexible catheter passed through the cervix.
- Intracervical Insemination (ICI): Semen is deposited directly into the cervical canal or against the external cervical os. This technique can utilize unwashed, liquefied semen and is sometimes employed in home-insemination protocols or baseline donor insemination models, though it yields lower per-cycle pregnancy rates than IUI.
- Intravaginal Insemination (IVI): The simplest and historically earliest modality, involving the injection of fresh, unwashed semen into the upper vaginal fornix adjacent to the cervix, commonly utilized in home insemination practices.
- Intratubal Insemination (ITI): An advanced, rarely utilized variation where spermatozoa are guided directly into the fallopian tubes via specialized catheters, either under ultrasound guidance or hysteroscopic visualization, aimed at overcoming severe tubal transport deficits.
- Homologous (Partner) Insemination: Insemination utilizing the biological partner’s semen, typically deployed to treat mild male-factor subfertility, physical or psychological coital difficulties, or cervical factor infertility.
- Heterologous (Donor) Insemination: The utilization of third-party screened donor semen from cryopreserved banks, utilized for azoospermic couples, single parents by choice, same-sex female couples, or when one partner carries a high-penetrance genetic disorder.
- Natural Cycle vs. Stimulated Cycle Insemination: Insemination performed alongside unmedicated, spontaneous ovulation versus insemination synchronized with controlled ovarian hyperstimulation using oral antiestrogens (e.g., clomiphene citrate, letrozole) or injectable gonadotropins to stimulate multifollicular development.
8. Examples & Illustrative Cases
To contextualize how artificial insemination operates across varied clinical settings, consider the following real-world clinical scenarios:
Case 1: Cervical Factor Infertility and Anatomical Stenosis
A 32-year-old female presents with a three-year history of primary infertility following a prior cervical loop electrosurgical excision procedure (LEEP) for cervical dysplasia. Evaluation reveals severe cervical scarring and impenetrable, scant cervical mucus during the peri-ovulatory phase, preventing sperm ascent. The male partner exhibits normal semen parameters. The clinical team initiates an unmedicated cycle monitored with serial transvaginal ultrasound. Upon documentation of a mature 19 mm dominant ovarian follicle and an endogenous LH surge, an intrauterine insemination (IUI) is performed twenty-four hours later using washed partner sperm. By navigating the sterile catheter directly through the stenotic external os and depositing 15 million progressively motile spermatozoa into the fundal endometrial cavity, the hostile cervical environment is completely bypassed, leading to a successful intrauterine pregnancy on the second cycle.
Case 2: Severe Male-Factor Subfertility and Ejaculatory Dysfunction
A 29-year-old male with a complete T10 spinal cord injury and his 28-year-old female partner seek fertility care. The male partner experiences neurogenic anejaculation but retains intact spermatogenesis. Using penile vibratory stimulation (PVS), an ejaculate is successfully retrieved. Semen analysis reveals moderate asthenozoospermia and elevated viscosity. The raw specimen undergoes double-density gradient centrifugation to extract the viable sperm fraction, yielding a post-wash total motile count of 8 million cells. The female partner undergoes mild ovarian stimulation with letrozole to induce the growth of two dominant follicles, triggered with an injection of human chorionic gonadotropin (hCG). IUI is conducted thirty-six hours post-trigger, resulting in successful fertilization and a full-term singleton birth.
9. Measurement & Assessment
The assessment of candidacy for artificial insemination, along with the monitoring of its procedural success, relies on a standardized set of diagnostic indices and laboratory thresholds:
Prior to initiating an artificial insemination protocol, clinicians establish baseline female tubal patency and pelvic anatomy using hysterosalpingography (HSG) or hysterosalpingo-contrast sonography (HyCoSy). Because IUI relies upon in vivo fertilization within the ampullary portion of the fallopian tube, at least one patent, functional fallopian tube is medically mandatory. Female ovarian reserve is simultaneously quantified using baseline serum Anti-Müllerian Hormone (AMH), Day-3 follicle-stimulating hormone (FSH), and transvaginal ultrasonographic Antral Follicle Count (AFC).
For the male partner or donor, standardized semen analysis performed according to World Health Organization (WHO) laboratory criteria measures ejaculate volume, total sperm concentration, vitality, progressive motility, and strict Krugher morphology. The single most predictive diagnostic variable for IUI success is the post-wash Total Motile Sperm Count (TMSC). Clinical data indicate that a post-wash TMSC exceeding 5 to 10 million progressively motile spermatozoa provides optimal pregnancy outcomes, whereas counts below 1 to 2 million motile cells demonstrate markedly depressed fecundity rates, often prompting direct transition to in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
During the treatment cycle itself, physiological monitoring involves serial follicular tracking via transvaginal ultrasound to measure the mean diameter of growing follicles (with target mature sizes typically ranging between 18 and 22 mm) alongside serum estradiol and progesterone measurements. A mid-luteal serum progesterone draw (taken seven days post-insemination) serves as a diagnostic metric to confirm robust ovulation, defined generally as a concentration exceeding 10 ng/mL in medicated cycles.
10. Applications & Practical Significance
The practical applications of artificial insemination encompass clinical medicine, bioethics, social demographics, and global veterinary industry:
In human clinical medicine, artificial insemination serves as the universal first-line active intervention for unexplained infertility, mild-to-moderate endometriosis (stages I and II), cervical hostility, and borderline semen deficiencies. Because it requires minimal laboratory infrastructure compared to the complex embryology suites mandated by IVF, IUI offers a widely accessible, low-cost therapeutic option. It is substantially less physiologically invasive for the female patient, avoiding the physical burdens, high medication doses, and surgical risks of transvaginal oocyte retrieval.
From a demographic and sociocultural standpoint, donor artificial insemination has become an instrumental technology for modern reproductive autonomy. It provides lesbian couples, single women by choice, and transgender individuals with a direct, legally regulated pathway to biological parenthood. Sperm banks operating within strict regulatory frameworks screen donors for infectious pathogens (HIV, Hepatitis B/C, Syphilis, CMV) and utilize expanded genetic carrier screening panels, minimizing the transmission of monogenic inherited diseases to offspring.
In veterinary medicine and commercial agriculture, artificial insemination is transformative. Within the global dairy and beef industries, a single genetically superior sire can inseminate thousands of cows across continents using cryopreserved semen straws, rapidly accelerating positive genetic traits such as milk yield, disease resistance, and feed efficiency. Concurrently, wildlife biologists deploy artificial insemination as an essential tool in conservation biology, maintaining genetic diversity among critically endangered species housed in zoological reserves without the logistical stress and behavioral hazards of moving adult animals across international borders.
11. Research & Empirical Evidence
An extensive body of clinical literature evaluates the efficacy and boundary conditions of artificial insemination in human reproduction. Landmark clinical trials, such as the Fast Track and Standard Treatment (FASTT) trial conducted by Reindollar et al. (2010), evaluated treatment algorithms for couples with unexplained infertility. The FASTT trial demonstrated that couples who engaged in three cycles of clomiphene citrate combined with IUI, followed immediately by in vitro fertilization, reached successful pregnancies faster and with lower overall healthcare expenditures than couples subjected to prolonged, conventional step-up therapies involving injectable gonadotropin-stimulated IUI cycles.
The comparative effectiveness of natural-cycle versus ovarian-stimulated IUI has been rigorously analyzed. A seminal Cochrane Systematic Review by Hughes (1997) and subsequent updates by Cantineau et al. (2014) established that the addition of controlled ovarian hyperstimulation significantly increases live birth rates in couples with unexplained infertility compared to IUI in spontaneous natural cycles alone. However, this therapeutic gain is paired with an increased rate of multiple gestation (twins, triplets), which carries higher risks of maternal-fetal morbidity, prompting many modern guidelines to recommend letrozole (an aromatase inhibitor) over gonadotropins to preserve mono-follicular or bi-follicular development.
Regarding donor insemination, retrospective and prospective registry studies, such as those published by the European Society of Human Reproduction and Embryology (ESHRE), consistently document cumulative pregnancy rates approaching 60% to 70% after six to nine cycles of donor IUI in women under thirty-five years of age with confirmed tubal patency. Across all empirical studies, maternal age remains the preeminent prognostic variable; cumulative live-birth rates decline sharply after thirty-eight years of age, and plunge below 5% per cycle for women over forty-two, reflecting age-related oocyte aneuploidy that mechanical sperm placement cannot remediate.
12. Cultural & Cross-Cultural Considerations
The global implementation of artificial insemination is governed by diverse cultural, religious, and legal frameworks, leading to sharp contrasts in international availability and acceptance:
Religious jurisprudence exhibits diverse perspectives on artificial insemination. In traditional Roman Catholic moral theology, as delineated in the 1987 Vatican instruction Donum Vitae, artificial insemination is deemed illicit, as the Catholic Church maintains that procreation must be the inseparable fruit of the conjugal sexual act, explicitly rejecting any technological separation of the unitive and procreative meanings of coitus. In contrast, mainstream Sunni Islamic jurisprudence broadly permits homologous artificial insemination (AIH) between legally married spouses, viewing it as a legitimate medical remedy for a physical affliction. However, Islamic authorities almost universally prohibit donor insemination (AID), categorizing third-party genetic material as a violation of lineage (nasab) and equating it functionally to non-coital adultery. In Jewish Halakhic law, rabbinic authorities generally endorse homologous insemination, while views on donor insemination vary, with extensive debate regarding the preservation of paternal lineage and tribal heritage.
Legal and regulatory environments show substantial variation worldwide. Several European nations (such as Sweden, the United Kingdom, and the Netherlands) have enacted legislation eliminating donor anonymity, granting offspring the statutory right to access their donor’s identifying information upon reaching the age of majority. Other jurisdictions retain completely anonymous donor frameworks or operate dual-track systems. Furthermore, while many Western democracies guarantee non-discriminatory access to artificial insemination for single individuals and same-sex couples, numerous countries continue to restrict assisted reproductive technologies exclusively to married, heterosexual couples, driving cross-border reproductive tourism among prospective parents seeking equitable medical care.
13. Criticisms, Debates & Limitations
Despite its long-standing integration into modern clinical medicine, artificial insemination remains the subject of ongoing ethical, medical, and sociopolitical debates:
A primary clinical limitation is the ceiling effect regarding efficacy. Compared to in vitro fertilization—which typically offers cycle-specific success rates between 30% and 50% in younger cohorts—intrauterine insemination provides an average success rate of only 10% to 18% per completed cycle. Repeated failed IUI cycles can cause emotional distress, anxiety, and cumulative financial strain for patients, raising questions regarding the optimal number of cycles to attempt before recommending advanced assisted reproduction.
The historical risk of multiple pregnancies secondary to ovarian hyperstimulation represents another major critique. In an attempt to improve success rates, clinicians historically administered substantial doses of injectable gonadotropins, often resulting in high-order multiple pregnancies (triplets or higher) associated with extreme prematurity, neonatal intensive care admissions, and lifelong pediatric neurodevelopmental disabilities. Modern clinical protocols prioritize cycle-cancellation thresholds (e.g., withholding the hCG trigger if more than two or three follicles exceed 15 mm) and increasingly shift toward milder stimulation agents such as letrozole.
In donor insemination, contentious debates persist concerning donor recruitment, commercialization, and the psychological well-being of donor-conceived offspring. Concerns regarding consanguinity and the inadvertently high number of half-siblings generated by single “super-donors” have prompted many jurisdictions to establish strict legal limits on the number of families a single donor can serve. Moreover, activist organizations led by donor-conceived individuals argue that historic donor anonymity systematically violated fundamental human rights regarding genetic identity, medical history awareness, and ancestral knowledge, driving a global policy movement toward open-identity donation models.
14. Related Terms & Distinctions
To avoid clinical confusion, artificial insemination must be clearly distinguished from adjacent reproductive modalities:
- Artificial Insemination (AI) vs. In Vitro Fertilization (IVF): In artificial insemination, fertilization occurs entirely in vivo (inside the woman’s body) within the fallopian tubes after sperm are mechanically delivered to the uterus. In IVF, oocytes are surgically aspirated from the ovaries and combined with sperm in an embryology laboratory dish, where fertilization takes place in vitro (outside the body), with the resulting embryo transferred to the uterus days later.
- Intrauterine Insemination (IUI) vs. Intracervical Insemination (ICI): IUI requires laboratory-washed sperm placed directly inside the uterine cavity using an intrauterine catheter, bypassing the cervix. ICI places unwashed or washed semen into the cervical canal or vaginal vault, relying on the natural migration of sperm through the cervical mucus.
- Homologous Insemination (AIH) vs. Heterologous Insemination (AID): Homologous insemination utilizes the biological partner’s own gametes to achieve pregnancy, whereas heterologous insemination incorporates cryopreserved semen donated by an external third-party individual.
- Intracytoplasmic Sperm Injection (ICSI): An advanced micromanipulation offshoot of IVF wherein a single immobilized spermatozoon is directly injected into the cytoplasm of a mature oocyte. Unlike AI, ICSI completely circumvents natural cellular selection and penetration mechanisms.
15. Summary & Key Takeaways
Artificial insemination remains a cornerstone of contemporary reproductive medicine, balancing accessibility, cost-efficiency, and minimal physiological invasiveness. By instrumentally depositing concentrated cohorts of motile spermatozoa directly into the female reproductive tract at the precise biological window of ovulation, the procedure circumvents physical, immunological, and anatomical impediments to unassisted conception. Supported by centuries of scientific evolution, artificial insemination serves as an effective first-line therapy for mild male and female subfertility, an indispensable platform for donor-conceived family building, and a vital biological instrument within modern theriogenology and global species preservation.
References
- Cantineau, A. E., Janssen, M. J., Cohlen, B. J., & Allersma, T. (2014). Synchronised approach for intrauterine insemination in subfertile couples. Cochrane Database of Systematic Reviews, (12), CD006942. https://doi.org/10.1002/14651858.CD006942.pub3
- Hughes, E. G. (1997). The effectiveness of ovulation induction and intrauterine insemination in the treatment of persistent infertility: A meta-analysis. Human Reproduction, 12(9), 1865–1872. https://doi.org/10.1093/humrep/12.9.1865
- Ombelet, W., Dhont, N., Thijssen, A., Bosmans, E., & Kruger, T. (2014). Semen quality and intrauterine insemination for non-male factor subfertility: A review. Facts, Views & Vision in ObGyn, 6(4), 213–224. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286860/
- Reindollar, R. H., Regan, M. M., Neumann, P. J., Levine, B. S., Hornstein, M. D., Park, S. J., & Goldman, M. B. (2010). A randomized clinical trial to evaluate optimal treatment for unexplained infertility: The FASTT trial. Fertility and Sterility, 94(2), 488–499. https://doi.org/10.1016/j.fertnstert.2009.04.040
- World Health Organization. (2021). WHO laboratory manual for the examination and processing of human semen (6th ed.). World Health Organization. https://www.who.int/publications/i/item/9789240030787